Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
40S ribosomal protein S17 (RPS17) is a highly conserved structural protein that is an essential component of the small 40S subunit of the eukaryotic ribosome, which catalyzes protein synthesis in all cells. The RPS17 protein is involved in the assembly and stability of the ribosome as well as in the ribosome's primary function: translating messenger RNA into protein. RPS17 is cytoplasmic, contains nuclear and nucleolar localization signals, and concentrates in the nucleolus during ribosome assembly. Mutations or deletions in RPS17 cause Diamond-Blackfan anemia, a rare congenital disorder characterized by erythroid failure and various congenital anomalies, highlighting the protein’s critical role in hematopoiesis[1][2][3][4][5]. RPS17 is not a typical drug target (such as a receptor, enzyme, or transporter), and no approved drugs are known to specifically interact with or modulate this protein.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 40S ribosomal protein S17 (RPS17).